Presentation of BIOMIMESYS technology, the first organ-specific in vitro ECM, to develop innovative and predictive 3D cellular models for drug discovery – Academia Sinica, the 1st of November 2022

BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…

Development of HCS Pharma in Taïwan with an incubation process in the famous NHRI

We are really pleased to announce that we have officially created a representative office in Taïwan (company 仿生培養技術中心 ID number 90729614) which is directed by our partner, Joseph Chou 周肇隆 ジョーゼフ・チョウ, member of our advisory board. Thanks to Joseph and Professor Szecheng J. Lo, member of our scientific advisory board, all Read more…

Mechanical stress on cells observed in cancerous tumor can be reproduced with BIOMIMESYS® hydroscaffold

It is now well described that in tumor biopsies, the stiffness of the cancerous tissue is higher than the surrounding non-cancerous tissue of the same organ, with a described remodeling of the ECM. The increase in rigidity is related to the stimulation of fibroblasts that increase the synthesis of glycosaminoglycans, Read more…

Studying sprouting angiogenesis and vascular permeability in a 3D human in vitro model

Yukiko Matsunaga and Fabrice Soncin have developed a human microvessel-on-a-chip that allows to study pro- and anti-angiogenic effects of drugs, and their influence on vascular permeability. This model relies on the establishment of an initial vessel within a collagen-containing matrix, from which angiogenic sprouts will be induced by stimulation of Read more…